A Novel Group Therapy for Children With ADHD and Severe Mood Dysregulation

James G. Waxmonsky; Fran A. Wymbs; Meaghan E. Pariseau; Peter J. Belin; Daniel A. Waschbusch; Lysett Babocsai; Gregory A. Fabiano; Opeolowa O. Akinnusi; Jenifer L. Haak; William E. Pelham

doi:10.1177/1087054711433423

A Novel Group Therapy for Children With ADHD and Severe Mood Dysregulation

James G. Waxmonsky
, Fran A. Wymbs
, Meaghan E. Pariseau
, Peter J. Belin
, Daniel A. Waschbusch
, Lysett Babocsai
, Gregory A. Fabiano
, Opeolowa O. Akinnusi
, Jenifer L. Haak
, William E. Pelham

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Objective: No psychosocial treatments have been developed for children with ADHD and severe mood dysregulation (SMD) despite the significant prevalence and morbidity of this combination. Therefore, the authors developed a novel treatment program for children with ADHD and SMD. Method: The novel therapy program integrates components of cognitive-behavioral therapies for affect regulation with a parent-training intervention for managing recurrent defiant behaviors. It consists of nine 105-min child and parent groups run in unison. A pilot trial was conducted with seven participants with ADHD and SMD ages 7 to 12 who were on a stable stimulant regimen. Results: Six of the seven (86%) families completed the program. Participants showed large improvements in depressive symptoms, mood lability, and global functioning. Milder improvements in externalizing behaviors were observed. Conclusion: Results suggest the feasibility and potential efficacy of the therapy program for children with ADHD and SMD and warrant a larger controlled trial.

Original language	English (US)
Pages (from-to)	527-541
Number of pages	15
Journal	Journal of Attention Disorders
Volume	17
Issue number	6
DOIs	https://doi.org/10.1177/1087054711433423
State	Published - Aug 2013

All Science Journal Classification (ASJC) codes

Developmental and Educational Psychology
Clinical Psychology

Access to Document

10.1177/1087054711433423

Cite this

@article{4b115a6190ae40fca65ac0253271a616,

title = "A Novel Group Therapy for Children With ADHD and Severe Mood Dysregulation",

abstract = "Objective: No psychosocial treatments have been developed for children with ADHD and severe mood dysregulation (SMD) despite the significant prevalence and morbidity of this combination. Therefore, the authors developed a novel treatment program for children with ADHD and SMD. Method: The novel therapy program integrates components of cognitive-behavioral therapies for affect regulation with a parent-training intervention for managing recurrent defiant behaviors. It consists of nine 105-min child and parent groups run in unison. A pilot trial was conducted with seven participants with ADHD and SMD ages 7 to 12 who were on a stable stimulant regimen. Results: Six of the seven (86\%) families completed the program. Participants showed large improvements in depressive symptoms, mood lability, and global functioning. Milder improvements in externalizing behaviors were observed. Conclusion: Results suggest the feasibility and potential efficacy of the therapy program for children with ADHD and SMD and warrant a larger controlled trial.",

author = "Waxmonsky, \{James G.\} and Wymbs, \{Fran A.\} and Pariseau, \{Meaghan E.\} and Belin, \{Peter J.\} and Waschbusch, \{Daniel A.\} and Lysett Babocsai and Fabiano, \{Gregory A.\} and Akinnusi, \{Opeolowa O.\} and Haak, \{Jenifer L.\} and Pelham, \{William E.\}",

note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: All funding for this study was provided by a grant to Dr. Waxmonsky from the National Institutes of Mental Health (NIMH; MH080791; PI: Waxmonsky). In the past 3 years, Dr. Waxmonsky has received research funding from NIMH, Shire Pharmaceuticals, and Eli Lilly and served on the speaker{\textquoteright}s board for Novartis and the advisory board for Noven Pharmaceuticals. Dr. Waschbusch has received research support from Eli Lilly and Shire whereas Dr. Pelham and Dr. Fabiano have received research support from the Institute of Education Sciences and NIMH. Dr. Pelham has served on the advisory board for Noven Pharmaceuticals. The other authors have no conflicts to report.",

year = "2013",

month = aug,

doi = "10.1177/1087054711433423",

language = "English (US)",

volume = "17",

pages = "527--541",

journal = "Journal of Attention Disorders",

issn = "1087-0547",

publisher = "SAGE Publications Inc.",

number = "6",

}

TY - JOUR

T1 - A Novel Group Therapy for Children With ADHD and Severe Mood Dysregulation

AU - Waxmonsky, James G.

AU - Wymbs, Fran A.

AU - Pariseau, Meaghan E.

AU - Belin, Peter J.

AU - Waschbusch, Daniel A.

AU - Babocsai, Lysett

AU - Fabiano, Gregory A.

AU - Akinnusi, Opeolowa O.

AU - Haak, Jenifer L.

AU - Pelham, William E.

N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: All funding for this study was provided by a grant to Dr. Waxmonsky from the National Institutes of Mental Health (NIMH; MH080791; PI: Waxmonsky). In the past 3 years, Dr. Waxmonsky has received research funding from NIMH, Shire Pharmaceuticals, and Eli Lilly and served on the speaker’s board for Novartis and the advisory board for Noven Pharmaceuticals. Dr. Waschbusch has received research support from Eli Lilly and Shire whereas Dr. Pelham and Dr. Fabiano have received research support from the Institute of Education Sciences and NIMH. Dr. Pelham has served on the advisory board for Noven Pharmaceuticals. The other authors have no conflicts to report.

PY - 2013/8

Y1 - 2013/8

N2 - Objective: No psychosocial treatments have been developed for children with ADHD and severe mood dysregulation (SMD) despite the significant prevalence and morbidity of this combination. Therefore, the authors developed a novel treatment program for children with ADHD and SMD. Method: The novel therapy program integrates components of cognitive-behavioral therapies for affect regulation with a parent-training intervention for managing recurrent defiant behaviors. It consists of nine 105-min child and parent groups run in unison. A pilot trial was conducted with seven participants with ADHD and SMD ages 7 to 12 who were on a stable stimulant regimen. Results: Six of the seven (86%) families completed the program. Participants showed large improvements in depressive symptoms, mood lability, and global functioning. Milder improvements in externalizing behaviors were observed. Conclusion: Results suggest the feasibility and potential efficacy of the therapy program for children with ADHD and SMD and warrant a larger controlled trial.

AB - Objective: No psychosocial treatments have been developed for children with ADHD and severe mood dysregulation (SMD) despite the significant prevalence and morbidity of this combination. Therefore, the authors developed a novel treatment program for children with ADHD and SMD. Method: The novel therapy program integrates components of cognitive-behavioral therapies for affect regulation with a parent-training intervention for managing recurrent defiant behaviors. It consists of nine 105-min child and parent groups run in unison. A pilot trial was conducted with seven participants with ADHD and SMD ages 7 to 12 who were on a stable stimulant regimen. Results: Six of the seven (86%) families completed the program. Participants showed large improvements in depressive symptoms, mood lability, and global functioning. Milder improvements in externalizing behaviors were observed. Conclusion: Results suggest the feasibility and potential efficacy of the therapy program for children with ADHD and SMD and warrant a larger controlled trial.

UR - https://www.scopus.com/pages/publications/84880629045

UR - https://www.scopus.com/pages/publications/84880629045#tab=citedBy

U2 - 10.1177/1087054711433423

DO - 10.1177/1087054711433423

M3 - Article

C2 - 22373865

AN - SCOPUS:84880629045

SN - 1087-0547

VL - 17

SP - 527

EP - 541

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

IS - 6

ER -

A Novel Group Therapy for Children With ADHD and Severe Mood Dysregulation

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this